This study is testing an experimental drug called "LY3819253" that will provide antibodies that is thought to fight the COVID-19 virus.The subject will receive the study drug (either the experimental study drug or the placebo) only once, on the day he/she joins the study (study "Day 0"). The subject will get it by an intravenous (IV) drip through a tube attached to a needle in the arm. This is called an infusion. As part of the study the subject will also get a study drug called remdesivir once a day intravenously for up to 10 days while in the hospital, as care for COVID-19, unless the study doctor thinks remdesivir would not be safe to be taken. The study will last for 90 days.
This is a study to see if treatment with a single dose of REGN10933+REGN10987 is well tolerated and reduces COVID-19 viral load. REGN10933+REGN10987 is an investigational medication which means it has not been approved by the FDA to treat COVID-19 or any other disease. Adults who are not hospitalized with COVID-19 (i.e. outpatient or ambulatory) and have a positive test for COVID-19 may be eligible for this study. Participants will be randomly assigned to receive a one-time infusion of the medication or placebo. Study participation will last about 60 days and may include visits to the research clinic as well as home-based visits.
The purpose of this study is to see if a vaccine that is being developed to prevent people from getting sick with COVID-19 is safe and effective and also to see how well it is tolerated. Participants will receive a shot of either the vaccine or a placebo twice: once on Day 1 and a booster shot on Day 57. Participants will have blood drawn several times over a 24 month period to assess the immune system response (how your body fights off the virus). Participation will last about 24 months. Participants will receive payment in return for their time and effort.
The CRISIS2 trial will study out-patients (non-hospitalized patients) who have a
positive SARS-CoV-2 test and are symptomatic. Subjects will be randomized to
receive standard of care (SOC) + 5 days of brequinar or SOC + 5 days of placebo.
The purpose of this study is to determine if the in vitro antiviral activity of
brequinar can be duplicated in patients infected with SARS-CoV-2 by measuring
the effect of brequinar on viral shedding. Importantly, the safety and tolerability of
brequinar will also be determined in these patients. The results of this proof-of concept study will inform future studies that will help determine if brequinar is a
safe and effective drug for the treatment of SARS-CoV-2 infection.
You are being asked to participate in a research study because you have been diagnosed or are suspected of having COVID-19 infection. The reason for this study is to collect nasal swabs from people diagnosed or suspected of having the 2019-nCoV (coronavirus) to use in the future to possibly help make new tests for detecting this virus, and/or make current tests better.
A company called Becton Dickinson & Company, the sponsor of the study, is paying for this study. Becton Dickinson & Company is also paying the study doctor to do this study.Approximately 2000 people will be enrolled across the US.
This studyis designed to look at the effectiveness of a new technology call Nanotechnology Biomarker Tagging (NBT) in detecting COVID-19 infection using breath samples of patients. Participation in this study is expected to take less than one month and will consist of a breath sample being taken by the research team, a cheek swab being taken by the research team, a questionnaire that will be completed by the participant with the help of the research teams, and a review of your medical record.
BLUE CORAL is an observational, biorepository study for patients who are hospitalized with COVID-19. The study collects various data and biospecimens, such as blood, urine, and tracheal aspirates, during the patient's hospital stay. The data and biospecimens collected will be used to provide greater knowledge on the biology and epidemiology of COVID-19.
To assess the safety, tolerability and effects of SBI-101 therapy in COVID-19 subjects with acute kidney injury (AKI) receiving renal replacement therapy. The study product is a device that is added to the dialysis machine and is being developed by Sentien Biotechnologies. Not everyone will receive the study product. A total of 8 subjects will receive the study product and 4 subjects will receive their standard of care treatment. The study product, called SBI-101, is a device that is added to the dialysis machine. Inside the device are human mesenchymal stromal cells (MSC). These cells do not enter your blood. The study duration is approximately 6 months.
We will aim to enroll children who have had a nasal swab test showing infection with SARS-CoV-2, the virus that causes COVID-19, or children with a serious complication of COVID-19 called the Multi-system Inflammatory Syndrome in Children (MIS-C). This study does not offer any treatment for COVID-19 or MIS-C. The purpose of the study is to collect information that will help us understand what happens to children and young adults who get infected with SARS-CoV-2, and how their immune system responds. Most of the information that we will collect is part of usual care for young people who have COVID-19 or MIS-C. In addition, we will do some extra clinical and blood tests. Children and young adults who are enrolled in the study will be followed for one year. Our goal is to enroll up to 250 children and young adults (up to the time of your 21st birthday) from about 20 hospitals in the United States. At our center we plan to enroll about 10 participants.
This observational study will determine the spectrum and time course of coronary artery involvement, left ventricular (LV) systolic function, and arrhythmias or conduction system disturbances within the first year from illness onset, and to define associated clinical and laboratory factors in a cohort of MIS-C affected patients.